Small Intestinal Carcinoma
Associated Genetic Biomarkers
NCI Definition: A carcinoma arising from the small intestine. The vast majority are adenocarcinomas. The remaining cases are adenosquamous, squamous, or undifferentiated carcinomas. 
Small intestinal carcinomas most frequently harbor alterations in KRAS, TP53, APC, PIK3CA, and SMAD4 .
KRAS Mutation, KRAS Exon 2 Mutation, TP53 Mutation, KRAS Codon 12 Missense, and TP53 c.217-c.1178 Missense are the most common alterations in small intestinal carcinoma .
There are 7 clinical trials for small intestinal carcinoma, of which 4 are open and 3 are completed or closed. Of the trials that contain small intestinal carcinoma as an inclusion criterion, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (1 open).
ERBB2, HER2, and Microsatellite are the most frequent gene inclusion criteria for small intestinal carcinoma clinical trials .
Cish crispr til, nhs-il12, and aldesleukin are the most common interventions in small intestinal carcinoma clinical trials.
Significant Genes in Small Intestinal Carcinoma
ALK is altered in 3.95% of small intestinal carcinoma patients .
ALK is an inclusion eligibility criterion in 1 clinical trial for small intestinal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and small intestinal carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
ERBB2 is altered in 11.18% of small intestinal carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for small intestinal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and small intestinal carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.